Erlotinib Hydrochloride CAS 183319-69-9 Ma'ema'e >99.0% (HPLC)
ʻO ka mea hana alakaʻi a me ka mea hoʻolako o Erlotinib Hydrochloride Intermediates
Erlotinib Hydrochloride CAS 183319-69-9
3-Ethynylaniline CAS 54060-30-9
6,7-Bis(2-Methoxyethoxy)-3H-Quinazolin-4-one CAS 179688-29-0
Please contact: alvin@ruifuchem.com
Inoa Kimia | ʻO Erlotinib Hydrochloride |
Nā huaʻōlelo like | Erlotinib HCl;Tarceva;CP-358774 Hydrochloride;6,7-Bis(2-methoxyethoxy)-4-(3-ethynylanilino)quinazoline Hydrochloride;N-(3-Ethynylphe nyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine HCl |
Helu CAS | 183319-69-9 |
Helu CAT | RF-PI2242 |
Kūlana Kūʻai | Ma ka waihona, hoʻonui ʻia a hiki i nā tona |
ʻĀpana Molekala | C22H24ClN3O4 |
Kaumaha Molecular | 429.90 |
Brand | Kemika Ruifu |
'ikamu | Nā kikoʻī |
Ka nana aku | Keʻokeʻo a i ka pauka kristal keʻokeʻo |
ʻIkepili | A: IR: E pili ana i ka Spectrum Reference B: HPLC: E pili ana i ka Reference RT |
Ka hikiwawe | Hiki ke hoʻoheheʻe ʻia i loko o ka wai, hiki ke hoʻoheheʻe ʻia i ka Methanol a hiki ʻole ke hoʻoheheʻe ʻia i ka Acetonitrile, Acetone, Ethyl Acetate a me Hexane. |
Lae hehee | 223.0~229.0 ℃ |
Nalo ma ka maloo | <0.50% |
Koena ma ka Ignition | <0.20% |
Nā Metala Kaumaha | <20ppm |
Hoʻokahi haumia | <0.50% |
Huina paumaele | <1.00% |
Nā mea hoʻoheheʻe koena | |
Pyridine | <4000ppm |
Chloroform | <4000ppm |
DMF | <3000ppm |
Maʻemaʻe / Kaʻina Hanana | >99.0% |
Hana ʻIke / ʻIke | 98.5%~101.0% (Caculated on Anhydrous Basis) |
Kūlana hoʻāʻo | Kūlana ʻoihana |
Hoʻohana | API |
Pūʻolo: ʻOmole, ʻeke ʻeke Aluminum, 25kg / pahu pahu pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.
Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;E pale i ka malamalama a me ka wai
ʻO Erlotinib Hydrochloride (CAS: 183319-69-9) kahi mole liʻiliʻi o ka epidermal growth factor receptor tyrosine kinase reversible inhibitor, i hoʻohana nui ʻia i ka mālama ʻana i ka maʻi maʻi ʻaʻai kūloko a i ʻole metastatic non small cell lung cancer a me ka laina lua a i ʻole ʻekolu laina lapaʻau. maʻi ʻaʻai pancreatic.Ua ʻae ʻia ʻo Erlotinib Hydrochloride i Nowemapa, 2004, no ka mālama ʻana i ka maʻi maʻi maʻi maʻi maʻi ʻaʻole liʻiliʻi.Aia ia i ka papa like me Gefitinib, kekahi quinazoline i ʻae ʻia no ka mālama ʻana i ka maʻi maʻi maʻi maʻi maʻi, akā me nā waiwai pharmacokinetic i hoʻomaikaʻi ʻia.Ua hoʻokumu ʻia ka mole e Pfizer a ua hoʻomaka ʻia ka hoʻomohala ʻana ma ka hui pū ʻana me OSI, ka mea i lawe i nā kuleana piha i ka lāʻau i ka wā i hui pū ai ʻo Pfizer me Warner Lambert.Ma hope mai, ua komo ʻo Genentech/Roche i ka ʻaelike laikini me OSI e hoʻomohala a kūʻai aku i ka lāʻau lapaʻau ma US a me ka honua.Selective epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor.Atineoplastic.ʻO Erlotinib Hydrochloride kahi mea hoʻopiʻi HER1 / EGFR me IC50 o 2 nM.Loaʻa ka Erlotinib HCl ma ke ʻano he 25-, 100-, a me 150-mg papa no ka hoʻokele waha.